Updates from the UK at ASH
Dr Graham Collins (Oxford, UK) discusses real-world data from patients treated with CD19 CAR-T in England. He then reviews data presented on the risk of fracture following front-line R-CHOP… read more.
Dr Graham Collins (Oxford, UK) discusses real-world data from patients treated with CD19 CAR-T in England. He then reviews data presented on the risk of fracture following front-line R-CHOP… read more.
Dr Steven Horwitz (New York, USA) discusses new directions for treating PTCL. Written by Thomas R. Collins.
Using rituximab in combination with chemotherapy — tailored based on risk profile and response speed — produced good results in children, adolescents and young adults with classic Hodgkin lymphoma,… read more.
Dr Alison J. Moskowitz (New York, USA) and Dr Graham Collins (Oxford, UK) review the long-term follow up data from brentuximabvedotin and nivolumab for R/R Hodgkin lymphoma Written by Thomas R. Collins
Dr Alison J. Moskowitz (New York, USA) highlights the long-term follow up data for single-agent brentuximab vedotin as pre-transplant salvage.
Dr Wendy Osborne (Newcastle upon Tyne, UK) highlights data coming from the H10 and AHL2011 trials. She then reviews data presented on the long-term follow up of the HD14… read more.
The American Society of Hematology (ASH) Annual Meeting in 2019, held in Orlando, Florida, as usual gave interesting updates in the management of lymphoma.
The final analyses of Checkmate 227, part 1 should help to position nivolumab + ipilimumab combination treatment .. Written by Christine Clark
The search for effective therapeutic targets in small cell lung cancer (SCLC) continues and a number of options have been identified. In the meantime the results of CASPIAN… read more.
Oligorecurrent and oligoprogressive NSCLC represent a treatment challenge. A case example of synchronous oligometastatic disease provided the framework for expert discussion…….. Written by Christine Clark.
Advances in the use of immunotherapy in thoracic malignancies continued in 2019 with the publication of the results of a number of landmark trials. This has prompted some… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.